MX2023001287A - Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. - Google Patents
Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.Info
- Publication number
- MX2023001287A MX2023001287A MX2023001287A MX2023001287A MX2023001287A MX 2023001287 A MX2023001287 A MX 2023001287A MX 2023001287 A MX2023001287 A MX 2023001287A MX 2023001287 A MX2023001287 A MX 2023001287A MX 2023001287 A MX2023001287 A MX 2023001287A
- Authority
- MX
- Mexico
- Prior art keywords
- specific
- antigen
- methods
- making
- minibanks
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Las modalidades de la invención incluyen composiciones universales de células T específicas de antígeno y métodos para prepararlas y usarlas. Las modalidades de la invención también incluyen métodos para identificar y seleccionar donantes adecuados para su uso en la construcción de minibancos de donantes de líneas de células T específicas de antígeno; minibancos de donantes de líneas de células T específicas de antígeno; composiciones universales de células T específicas de antígeno que comprendan una pluralidad de líneas de células T específicas de antígeno de dichos minibancos de donantes, y bancos de donantes formados por una pluralidad de tales minibancos. La presente invención incluye métodos para tratar una enfermedad o afección que comprenden administrar a un paciente al menos una composición universal de células T específicas de antígeno descrita en el presente documento.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880006P | 2019-07-29 | 2019-07-29 | |
| US201962887802P | 2019-08-16 | 2019-08-16 | |
| US202063054161P | 2020-07-20 | 2020-07-20 | |
| PCT/US2020/044080 WO2021021937A1 (en) | 2019-07-29 | 2020-07-29 | Antigen-specific t cell banks and methods of making and using the same therapeutically |
| PCT/US2021/016266 WO2022025984A1 (en) | 2019-07-29 | 2021-02-02 | Universal antigen-specific t cell banks and methods of making and using the same therapeutically |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001287A true MX2023001287A (es) | 2023-03-22 |
Family
ID=74230834
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001322A MX2022001322A (es) | 2019-07-29 | 2020-07-29 | Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente. |
| MX2023001287A MX2023001287A (es) | 2019-07-29 | 2021-02-02 | Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001322A MX2022001322A (es) | 2019-07-29 | 2020-07-29 | Bancos de células t específicas de antígeno y métodos para fabricar y usar los mismos terapéuticamente. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230295565A1 (es) |
| EP (2) | EP4003378A4 (es) |
| JP (2) | JP2022542968A (es) |
| KR (2) | KR20220051348A (es) |
| CN (2) | CN114502180A (es) |
| AU (2) | AU2020322790A1 (es) |
| BR (2) | BR112022001596A2 (es) |
| CA (2) | CA3149145A1 (es) |
| CO (2) | CO2022001972A2 (es) |
| IL (2) | IL300179A (es) |
| MX (2) | MX2022001322A (es) |
| WO (2) | WO2021021937A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PL3591047T3 (pl) | 2012-02-09 | 2022-12-05 | Baylor College Of Medicine | Mieszanki peptydowe do wytwarzania wielowirusowych ctl o szerokiej swoistości |
| IL288241B2 (en) * | 2012-06-11 | 2023-10-01 | Wilson Wolf Mfg Corporation | Improved cell culture methods for stress cell therapy |
| EP4290238A2 (en) | 2015-09-18 | 2023-12-13 | Baylor College of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| CN114452388A (zh) * | 2022-03-07 | 2022-05-10 | 北京大学第一医院 | 一种降低血循环系统中eb病毒拷贝数的方法和系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0107628D0 (en) * | 2001-03-27 | 2001-05-16 | Avidex Ltd | Substances |
| AU2014351871B2 (en) * | 2013-11-22 | 2020-02-13 | Cellectis | Method for generating batches of allogeneic T-cells with averaged potency |
| EP3215165B1 (en) * | 2014-11-05 | 2020-12-23 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line and donor thereof for adoptive cellular therapy |
| CN107921065A (zh) * | 2015-06-26 | 2018-04-17 | 纪念斯隆-凯特林癌症中心 | 通过t细胞疗法治疗cmv视网膜炎的方法 |
| MX2018013959A (es) * | 2016-05-25 | 2019-08-22 | Council Queensland Inst Medical Res | Metodos para tratar enfermedad autoinmune usando celulas t alogenicas. |
| WO2018055191A1 (en) * | 2016-09-26 | 2018-03-29 | Tessa Therapeutics Pte. Ltd. | T cell expansion method |
| WO2018232467A1 (en) * | 2017-06-22 | 2018-12-27 | The Westmead Institute for Medical Research | ADOPTIVE T-LYMPHOCYTE THERAPY 2 |
| CN111213210A (zh) * | 2017-09-06 | 2020-05-29 | 河谷控股Ip有限责任公司 | Hla组织匹配及用于其的方法 |
-
2020
- 2020-07-29 WO PCT/US2020/044080 patent/WO2021021937A1/en active Application Filing
- 2020-07-29 JP JP2022506160A patent/JP2022542968A/ja active Pending
- 2020-07-29 CN CN202080067987.2A patent/CN114502180A/zh active Pending
- 2020-07-29 KR KR1020227006698A patent/KR20220051348A/ko unknown
- 2020-07-29 MX MX2022001322A patent/MX2022001322A/es unknown
- 2020-07-29 CA CA3149145A patent/CA3149145A1/en active Pending
- 2020-07-29 AU AU2020322790A patent/AU2020322790A1/en active Pending
- 2020-07-29 EP EP20847823.0A patent/EP4003378A4/en active Pending
- 2020-07-29 BR BR112022001596A patent/BR112022001596A2/pt unknown
-
2021
- 2021-02-02 AU AU2021318102A patent/AU2021318102A1/en active Pending
- 2021-02-02 IL IL300179A patent/IL300179A/en unknown
- 2021-02-02 CN CN202180066389.8A patent/CN116261466A/zh active Pending
- 2021-02-02 US US18/018,552 patent/US20230295565A1/en active Pending
- 2021-02-02 MX MX2023001287A patent/MX2023001287A/es unknown
- 2021-02-02 JP JP2023505972A patent/JP2023536840A/ja active Pending
- 2021-02-02 WO PCT/US2021/016266 patent/WO2022025984A1/en active Application Filing
- 2021-02-02 KR KR1020237006817A patent/KR20230058398A/ko unknown
- 2021-02-02 BR BR112023001642A patent/BR112023001642A2/pt not_active Application Discontinuation
- 2021-02-02 EP EP21848816.1A patent/EP4188397A1/en active Pending
- 2021-02-02 CA CA3177064A patent/CA3177064A1/en active Pending
-
2022
- 2022-01-27 IL IL290163A patent/IL290163A/en unknown
- 2022-02-23 CO CONC2022/0001972A patent/CO2022001972A2/es unknown
-
2023
- 2023-02-15 CO CONC2023/0001681A patent/CO2023001681A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022001596A2 (pt) | 2022-06-07 |
| EP4188397A1 (en) | 2023-06-07 |
| JP2023536840A (ja) | 2023-08-30 |
| BR112023001642A2 (pt) | 2023-10-03 |
| CO2023001681A2 (es) | 2023-05-08 |
| CO2022001972A2 (es) | 2022-04-08 |
| CA3177064A1 (en) | 2022-02-03 |
| CN116261466A (zh) | 2023-06-13 |
| AU2021318102A1 (en) | 2023-03-16 |
| EP4003378A1 (en) | 2022-06-01 |
| CA3149145A1 (en) | 2021-02-04 |
| WO2022025984A1 (en) | 2022-02-03 |
| WO2021021937A1 (en) | 2021-02-04 |
| KR20220051348A (ko) | 2022-04-26 |
| CN114502180A (zh) | 2022-05-13 |
| IL300179A (en) | 2023-03-01 |
| AU2020322790A1 (en) | 2022-03-03 |
| JP2022542968A (ja) | 2022-10-07 |
| MX2022001322A (es) | 2022-05-24 |
| US20230295565A1 (en) | 2023-09-21 |
| IL290163A (en) | 2022-03-01 |
| EP4003378A4 (en) | 2023-08-23 |
| KR20230058398A (ko) | 2023-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001287A (es) | Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos. | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| EA201991692A1 (ru) | Иммуносконструированные плюрипотентные клетки | |
| NZ765695A (en) | Immune cell organoid co-cultures | |
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| MX2020003351A (es) | Metodos, composiciones y elementos implantables que comprenden celulas activas. | |
| PE20191717A1 (es) | Dominio de union antigeno anti-trbc1 | |
| BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
| MX2020010999A (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos. | |
| BR112019001923A2 (pt) | moduladores de nmda de espiro-lactama e métodos de sua utilização | |
| BRPI0821145B8 (pt) | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido | |
| CR20220329A (es) | Anticuerpos anti–mertk y metodos de uso de los mismos | |
| PH12020551976A1 (en) | SELECTIVE TREG STIMULATOR RUR20kD-IL-2 AND RELATED COMPOSITIONS | |
| MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MX2021005085A (es) | Formulacion de anticuerpo. | |
| BR112019002529A2 (pt) | anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo | |
| MX2020004063A (es) | Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados. | |
| PH12019500949A1 (en) | Ror-gamma modulators | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| MX2023012048A (es) | Composiciones y metodos para inhibir cetohexoquinasa (khk). | |
| Hoff et al. | Recipient HLA-C haplotypes and microRNA 148a/b binding sites have no impact on allogeneic hematopoietic cell transplantation outcomes | |
| PH12019500482A1 (en) | Antibody for treating autoimmune diseases | |
| WO2019098759A3 (ko) | 형질전환된 인간세포 및 이의 용도 |